乳腺癌组织中PRDX4、ALG3的表达及与临床病理特征和预后的关系

Expression of PRDX4 and ALG3 in breast cancer and their relationship with clinicopathological features and prognosis

目的探讨过氧化物还原酶4(PRDX4)、α-1,3-甘露糖基转移酶(ALG3)在乳腺癌组织中的表达情况及其与临床病理特征和预后的关系。方法收集2020年6月—2022年6月武汉市第一医院甲状腺乳腺外科诊治乳腺癌患者126例的癌组织、癌旁组织及相关资料,采用免疫组化法检测组织中PRDX4、ALG3蛋白水平,依据表达情况分为阴性、阳性表达组;Kaplan-Meier生存曲线分析PRDX4、ALG3蛋白表达与乳腺癌患者2年预后的关系;采用多因素Cox回归分析筛选2年预后影响因素。结果癌组织中PRDX4阳性表达、ALG3阳性表达比例高于癌旁组织(χ^(2)/P=68.980/<0.001、72.278/<0.001)。PRDX4阳性表达组、ALG3阳性表达组T2~4期、N1~2期、组织低分化、有淋巴结转移比例高于PRDX4阴性表达组、ALG3阴性表达组(PRDX4:χ^(2)/P=8.749/0.003、14.655/<0.001、15.935/<0.001、15.154/<0.001;ALG3:χ^(2)/P=7.653/0.006、9.559/0.002、17.594/<0.001、9.433/0.002)。PRDX4阳性表达乳腺癌患者2年生存率低于PRDX4阴性表达患者(61.18%vs.85.37%,χ^(2)=7.572,P=0.006);ALG3阳性表达乳腺癌患者2年生存率低于ALG3阴性表达患者(60.67%vs.89.19%,χ^(2)=9.943,P=0.002)。死亡组T2~4期、N1~2期比例高于生存组(χ^(2)/P=8.188/0.004、8.022/0.005)。PRDX4阳性表达、ALG3阳性表达是乳腺癌患者2年内死亡的独立危险因素[HR(95%CI)=2.759(1.462~5.207)、2.805(1.469~5.356)]。结论乳腺癌患者癌组织PRDX4、ALG3的阳性表达率均高于癌旁组织,二者高表达与T分期、N分期、组织分化程度、淋巴结转移及预后有关。

Objective To investigate the expression of peroxiredoxin 4(PRDX4)and alpha-1,3-mannosyltransferase(ALG3)in breast cancer and their relationship with clinicopathological features and prognosis.Methods The cancerous tissue,paracancerous tissue and related data of 126 patients with breast cancer diagnosed and treated in General Surgery Department of Renhe Hospital Affiliated to Three Gorges University during June 2020 to June 2022 were retrospectively collected.Immunohistochemistry was used to measure the expression of PRDX4 and ALG3 proteins in tissues.According to the protein expression,patients were separated into negative expression group and positive expression group.Multivariate Cox regression analysis was applied to screen for factors affecting 2-year prognosis.Results The proportions of PRDX4 positive expression and ALG3 positive expression in cancer tissues were higher than those in adjacent tissues(χ^(2)/P=68.980/<0.001,72.278/<0.001).The proportions of T2-T4,N1-N2,poorly differentiated tissues,and lymph node metastasis in the PRDX4 positive expression group and ALG3 positive expression group were higher than those in the PRDX4 negative expression group and ALG3 negative expression group(χ^(2)/P=8.749/0.003,14.655/<0.001,15.935/<0.001,15.154/<0.001;7.653/0.006,9.559/0.002,17.594/<0.001,9.433/0.002).The 2-year survival rate of patients with positive expression of PRDX4(52/85,61.18%)was lower than that of patients with negative expression of PRDX4(35/41,85.37%)in breast cancer(χ^(2)=7.572,P=0.006).The 2-year survival rate of patients with positive expression of ALG3(54/89,60.67%)was lower than that of patients with negative expression of ALG3(33/37,89.19%)in breast cancer(χ^(2)=9.943,P=0.002).The proportion of T2-T4 and N1-N2 stages in the death group was higher than that in the survival group(χ^(2)/P=8.188/0.004,8.022/0.005).PRDX4 positive expression and ALG3 positive expression were independent risk factors for death of breast cancer patients within 2 years[HR(95%CI)=2.759(1.462~5.207),2.805(1.469~5.356)].Conclusion The positive expression rates of PRDX4 and ALG3 in breast cancer tissues are higher than those in adjacent tissues.The high expression of both is related to T stage,N stage,tissue differentiation degree,lymph node metastasis,and prognosis.